The ehcoBUTLER Idea: Nowadays, it is a fact that Europe is ageing. A common characteristic of elders is the frequent occurrence of either physical or mild cognitive impairments. This situation brings new challenges in how to improve the independence and quality of life of elderly people and promote their good health in different ways. The ehcoBUTLER project addresses this challenge by developing an ICT technological platform with both leisure and care apps. The main objective of ehcoBUTLER is to demonstrate the socio-economic benefits from the deployment of several innovative and user led ICT pilot projects based on different business models in order to be able to translate promising results into scalable practice across Europe. How the objectives will be achieved: The ehcoBUTLER Consortium is composed by a multidisciplinary combination of specialist partners on their areas and responsibilities, in order to satisfy the requirements emerging from the EU Call and the particular PHC-20 topic. With this consortium we expect to contribute to break the technological barrier that exists nowadays between the elderly and the ICTs, encouraging the e-Inclusion, to facilitate psychological and cognitive techniques and support procedures, both for the elderly people and for the informal and formal caregivers, to develop an interoperable and open ICT platform particularly designed and adapted to elderly people, to demonstrate the ROI from several four business models based on the deployment of this ICT platform and to generate an ecosystem for apps provider that will allow end users to integrate all the leisure and care related activities in just one platform. To ensure that the platform can be scaled to an operational deployment in the European Market we will deploy ehcoBUTLER in 5 countries and 7 pilot sites to reach the higher number of users and to test the suitability of ehcoBUTLER in different but related business cases.

Coronary artery disease (CAD) is caused by the pathological process in which fat, cholesterol and calcium accumulate on the arterial wall. It is the leading cause of mortality in the world, affecting in 2019 about 200 million individuals or 2.5% of the global population and resulting in over 9 million deaths annually. The prevalence of CAD in the European Union (EU) reached 5.11% in 2019 . As a result, CAD-related deaths topped 973,000 in the EU in 2019. CAD incidence is expected to rise further due to the increased prevalence of risk factors including obesity, diabetes, and increasing age. For a patient with CAD, the care pathway still involves enormous variability and complexities. Inefficiencies and challenges in the treatment pathway are associated with poorer patient outcomes including recurrent cardiac events, incomplete revascularization in complex patients, and increased risk of mortality in patients with both acute and chronic CAD. Due to the low sensitivity or specificity of the standard diagnostic tests, 60% of CAD patients unnecessarily undergo an ICA, as they are found to have non-significant coronary stenoses and do not require revascularization. Coronary Computed Tomography Angiography (CCTA) uses X-ray technology and computer processing to create a detailed 3D image of the coronary arteries, revealing the degree of lumen obstruction. It provides non-invasive access to the coronary anatomy, also for asymptomatic patients who would normally not undergo invasive coronary angiography (ICA). Current guidelines adopted in the US, EU, and the UK recommend CCTA as a first-line test for evaluation of CAD, positioning it as a "gatekeeper" to the Cath lab. In COMBINE-CT, we will deliver a fully automated, vendor agnostic CCTA-enabled workflow for chronic CAD patients, covering diagnosis, treatment, and follow-up. COMBINE-CT will close the gaps in the existing workflow for the treatment of chronic CAD, to improve hospital efficiency and patient outcomes. AI-powered CCTA algorithms will enable definitive ischemia diagnosis, accurate patient stratification and efficient planning of the interventions, as well as patient specific follow-up. While our focus on CAD is justified by the large patient population, the CCTA-enabled diagnostic accuracy and seamless workflow, backed by the clinical evidence generated in five multicentre clinical trials, will be directly transferable to other clinical domains using CT. Interdisciplinarity is intrinsically built in the design of the COMBINE-CT consortium, combining expertise in cardiology, cardiovascular radiology, interventional cardiology, cardiac surgery, pharmacology – with expertise from engineering (medical imaging) and AI. The public-private partnership in COMBINE-CT integrates top knowledge on several medical disciplines (cardiology, radiology, interventional cardiology) with engineering, AI, design expertise - as well as the involvement of health economists and patient organizations, to fill in the gaps of the current CAD clinical pathways and prepare the ground for the imminent high-volume CCTA needs, beyond the research hospital setting. Clinical partners represent more than half of the COMBINE-CT consortium, ensuring access to large cohorts for stable CAD patients. COMBINE-CT will also lay the ground for further research that is likely to trigger a paradigm shift towards the use of imaging markers in the medical treatment evaluation and clinical trial design.

Our current understanding of the relationship between diet and the development of non-communicable disease (NCD) is limited by a number of factors. These include a lack of understanding of dietary mechanisms that drive NCD, inaccurate tools to collect dietary information, a nascent understanding of the role of personalised nutrition, and the lack of data in vulnerable groups where NCDs are often over-represented. The overarching aim of CoDiet is to develop a series of tools (through eight work packages) which will address the current gaps in our knowledge and lead to the development of a tool that will assess dietary-induced NCD risk. We will achieve this through the six objectives which will answer the challenges of the work programme 1: Development of AI-driven literature searching tools - bring clear understanding of large global literature in the field of physiological and metabolic links between diet and NCD 2: Enhance the understanding of NCD risk factors - we will bring a series of beyond the state of the technics to gain mechanistic insight 3: Understanding of the importance individual variation in response to diet to risk of NCD - this will give insight into the targeting of dietary NCD advice 4: Develop an enhanced method of dietary assessment using machine learning technologies - solving a fundamental problem in nutrition of lack of an accurate dietary tool 5: Develop an enhance diet-NCD monitoring tool - enabling change in NCD in response to diet to be monitored at the population level 6: Develop a dynamic interface between diet and NCD risk factor monitoring and policy - Ensuring CoDiet is applicable at a population level The investigation of these objectives and the answers they provide will open a pathway to enhancing the uptake of NCD protective diet at a population level

Obesity is one of the main population health threats worldwide, with a sustained increase in prevalence over the last decades and a constellation of co-morbidities that seriously hamper individual wellbeing and life-expectancy. Despite major research efforts, obesity treatments have proven of limited efficacy. Thus, effective prevention strategies are essential to avoid the full spectrum of metabolic complications of overweight during the life-course. Adult obesity is rooted on early maturational events, including pathophysiological and psychological determinants occurring during the gestational, infantile and/or adolescent periods, which globally remain ill defined. Identification of such early pathogenic mechanisms and markers of metabolic disease is key for active prevention and personalized management of body weight disorders later in life. Of note, pathogenic mechanisms and susceptibility to obesity are seemingly gender-dependent, but this aspect remains underexplored and may compromise effectiveness of preventive measures and treatments tackling obesity and its complications. eprObes (for early Prevention of Obesity) is a multidisciplinary, patient-centered project, involving clinical studies targeting different maturational windows, coupled with cognitive, mental health, life-style and behavioral studies, as well as mechanistic analyses in suitable preclinical models, whose major aim is to define effective strategies for active prevention of obesity during the life-course, with particular focus on early developmental events, from prenatal (including peri-conceptional) to pubertal periods, and determinants of feeding behaviors. Multi-omics studies and integral analysis of eprObes data, assisted by bioinformatic technologies and artificial intelligence, will permit definition of tailored preventive measures and life-style interventions, at key maturational periods, to avoid excessive body weight gain and lifetime metabolic complications in both sexes.

"PROPHET - a PeRsOnalized Prevention roadmap for the future HEalThcare" will develop a Strategic Research and Innovation Agenda (SRIA) for Personalized Prevention, in order to support the implementation of innovative, sustainable and effective personalized programmes to prevent common chronic diseases. Technological biomedical advances (including omics data and digital tools) make risk stratification at the individual level possible. However, development of Personalized Prevention approaches must be accompanied by healthcare system transition, including citizen engagement, healthcare professional education and addressing organisational, social and legal issues. PROPHET will be centred around stakeholder engagement and the SRIA co-creation process in relation to three main strands of activities: Mapping, Assessment, and Building. Firstly, we will summarize, evaluate and discuss with the relevant stakeholders the extent to which all these new technologies can synergise (Mapping). Secondly, we will design a holistic framework (the PROPHET Framework) that will include all the necessary aspects to appraise Personalized Prevention approaches and their adoption by Public Health Authorities (Assessment). Thirdly, we will support the introduction of Personalised Prevention Programmes by providing guidelines for their design, engaging with healthcare professionals (especially those working with policy makers), and increasing health literacy at the population level on the benefits of Personalized Prevention (Building). PROPHET will liaise with other key current and forthcoming initiatives at EU level, such as ICPerMed, European Partnership (EP) PerMed, the CSA Beyond 1 Million Genomes (B1MG), and the EP on Transforming Health and Care Systems. The consortium consists of 18 beneficiaries and 2 affiliated entities across 12 EU Countries, and a large number of stakeholders already engaged from different Target Groups.